New Partnership Between Brainomix and Pulmonary Fibrosis Foundation Enhances Patient Involvement in AI-Driven Care
In a significant advancement for pulmonary fibrosis care, Brainomix, an innovative medical technology company known for its AI-driven tools, has joined forces with the Pulmonary Fibrosis Foundation (PFF). This collaboration aims to enhance the understanding and care of individuals living with pulmonary fibrosis (PF) through the integration of patient and caregiver perspectives. The partnership specifically focuses on how AI-enhanced imaging, particularly e-Lung quantitative CT analysis, can better inform patients about their disease and aid in shared decision-making regarding treatment options.
The initiative, a multi-phase patient engagement program, seeks to delve deep into the insights and experiences of patients dealing with pulmonary fibrosis. By incorporating these perspectives, the collaboration aims to determine how objective metrics from AI-powered CT analyses can help both clinicians and patients understand the progression of the disease. The goal is to create a system where these imaging insights not only assist healthcare professionals in making informed decisions but also empower patients to engage actively in their care.
The Brainomix 360 e-Lung platform is at the core of this initiative. This FDA-cleared and CE-marked imaging tool revolutionizes lung care by enabling automatic quantification and visualization of radiographic features from CT Lung scans. This enables clinicians to track disease evolution over time effectively. The collaboration with the PFF is crucial as it blends the extensive clinical expertise of Brainomix with the PFF’s deep-rooted connections to the pulmonary fibrosis community, which includes patients, caregivers, and healthcare professionals.
Furthermore, the PFF is uniquely positioned to contribute invaluable insights by engaging its extensive network of patients and caregivers, thus ensuring that the program remains centered around the patient experience. Through this initiative, the PFF aims to highlight what information is most beneficial for patients about their disease, how they interpret visual data, and where the AI tools such as e-Lung can provide the greatest advantage in their treatment journey.
Dr. Michalis Papadakis, Co-Founder and CEO of Brainomix, emphasizes the primal role patients play in developing these technological tools. He asserts, “While our technology can deliver innovative imaging solutions, understanding how these tools influence clinical assessments and ensuring patients comprehend this information is crucial.” The partnership not only focuses on technological advancement but also lays the groundwork for improved communication between patients and their healthcare teams.
Scott Staszak, the President and CEO of the Pulmonary Fibrosis Foundation, adds, “People living with pulmonary fibrosis and their caregivers bring a vital perspective. We recognize the importance of integrating their voices into the creation of effective management strategies for this disease.” This collaborative effort underlines both organizations' dedication to fostering a patient-centered approach to pulmonary fibrosis treatment.
In addition to being part of the PROGRESS-PPF initiative—a broader collaboration involving Brainomix and Boehringer Ingelheim that explores the objective metrics provided by quantitative CT imaging—the partnership with the PFF is instrumental in placing patient perspectives at the forefront of research. This new partnership aims to augment the value of clinician insights derived from imaging data, particularly when considering options for starting, continuing, or modifying treatments, especially when mere symptoms may not fully depict changes in a patient’s condition.
In conclusion, the alliance between Brainomix and the Pulmonary Fibrosis Foundation signifies a transformative leap in pulmonary fibrosis care, placing an emphasis on understanding, communication, and shared decision-making harmoniously aimed at enhancing the lives of those affected by this challenging disease. The integration of cutting-edge technology with genuine patient involvement could reshape care methodologies, helping ensure that those with pulmonary fibrosis not only receive better care but have a voice in the treatment processes affecting their lives.
For more information on this vital initiative and to follow the journey of Brainomix and PFF, visit their respective websites and engage with the community’s shared mission of improving lung health.
The initiative, a multi-phase patient engagement program, seeks to delve deep into the insights and experiences of patients dealing with pulmonary fibrosis. By incorporating these perspectives, the collaboration aims to determine how objective metrics from AI-powered CT analyses can help both clinicians and patients understand the progression of the disease. The goal is to create a system where these imaging insights not only assist healthcare professionals in making informed decisions but also empower patients to engage actively in their care.
The Brainomix 360 e-Lung platform is at the core of this initiative. This FDA-cleared and CE-marked imaging tool revolutionizes lung care by enabling automatic quantification and visualization of radiographic features from CT Lung scans. This enables clinicians to track disease evolution over time effectively. The collaboration with the PFF is crucial as it blends the extensive clinical expertise of Brainomix with the PFF’s deep-rooted connections to the pulmonary fibrosis community, which includes patients, caregivers, and healthcare professionals.
Furthermore, the PFF is uniquely positioned to contribute invaluable insights by engaging its extensive network of patients and caregivers, thus ensuring that the program remains centered around the patient experience. Through this initiative, the PFF aims to highlight what information is most beneficial for patients about their disease, how they interpret visual data, and where the AI tools such as e-Lung can provide the greatest advantage in their treatment journey.
Dr. Michalis Papadakis, Co-Founder and CEO of Brainomix, emphasizes the primal role patients play in developing these technological tools. He asserts, “While our technology can deliver innovative imaging solutions, understanding how these tools influence clinical assessments and ensuring patients comprehend this information is crucial.” The partnership not only focuses on technological advancement but also lays the groundwork for improved communication between patients and their healthcare teams.
Scott Staszak, the President and CEO of the Pulmonary Fibrosis Foundation, adds, “People living with pulmonary fibrosis and their caregivers bring a vital perspective. We recognize the importance of integrating their voices into the creation of effective management strategies for this disease.” This collaborative effort underlines both organizations' dedication to fostering a patient-centered approach to pulmonary fibrosis treatment.
In addition to being part of the PROGRESS-PPF initiative—a broader collaboration involving Brainomix and Boehringer Ingelheim that explores the objective metrics provided by quantitative CT imaging—the partnership with the PFF is instrumental in placing patient perspectives at the forefront of research. This new partnership aims to augment the value of clinician insights derived from imaging data, particularly when considering options for starting, continuing, or modifying treatments, especially when mere symptoms may not fully depict changes in a patient’s condition.
In conclusion, the alliance between Brainomix and the Pulmonary Fibrosis Foundation signifies a transformative leap in pulmonary fibrosis care, placing an emphasis on understanding, communication, and shared decision-making harmoniously aimed at enhancing the lives of those affected by this challenging disease. The integration of cutting-edge technology with genuine patient involvement could reshape care methodologies, helping ensure that those with pulmonary fibrosis not only receive better care but have a voice in the treatment processes affecting their lives.
For more information on this vital initiative and to follow the journey of Brainomix and PFF, visit their respective websites and engage with the community’s shared mission of improving lung health.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.